Eligibility: Stg I, II, or III primary non-small cell lung cancer, breast cancer, or ovarian/fallopian tube cancer. Scheduled to receive taxane-based chemotherapy. To develop and validate a prediction model of peripheral neuropathy in patients receiving taxane-based chemotherapy regimens.
Learn more about the S1714 trail or call the Phoenixville Hospital Clinical Research Office at 610-983-1811.
